Modelling the efficacy of hyperthermia treatment

J R Soc Interface. 2013 Aug 28;10(88):20130527. doi: 10.1098/rsif.2013.0527. Print 2013 Nov 6.


Multimodal oncological strategies which combine chemotherapy or radiotherapy with hyperthermia, have a potential of improving the efficacy of the non-surgical methods of cancer treatment. Hyperthermia engages the heat-shock response (HSR) mechanism, the main component of which are heat-shock proteins. Cancer cells have already partially activated HSR, thereby hyperthermia may be more toxic to them relative to normal cells. On the other hand, HSR triggers thermotolerance, i.e. hyperthermia-treated cells show an impairment in their susceptibility to a subsequent heat-induced stress. This poses questions about efficacy and optimal strategy for anti-cancer therapy combined with hyperthermia treatment. To address these questions, we adapt our previous HSR model and propose its stochastic extension. We formalize the notion of a HSP-induced thermotolerance. Next, we estimate the intensity and the duration of the thermotolerance. Finally, we quantify the effect of a multimodal therapy based on hyperthermia and a cytotoxic effect of bortezomib, a clinically approved proteasome inhibitor. Consequently, we propose an optimal strategy for combining hyperthermia and proteasome inhibition modalities. In summary, by a mathematical analysis of HSR, we are able to support the common belief that the combination of cancer treatment strategies increases therapy efficacy.

Keywords: computational modelling; heat-shock response; hyperthermia; mass action kinetics; proteasome inhibitor; thermotolerance.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Combined Modality Therapy
  • Heat-Shock Response*
  • Humans
  • Hyperthermia, Induced*
  • Models, Biological*
  • Neoplasms / metabolism*
  • Neoplasms / pathology
  • Neoplasms / therapy*
  • Proteasome Inhibitors / therapeutic use
  • Stochastic Processes


  • Proteasome Inhibitors